



PATENT

13/B

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

JUL 31 2002

TECH CENTER 1600/2900

Applicants : Alexander Gaiger et al.
Application No. : 09/684,361
Filed : October 6, 2000
For : COMPOSITIONS AND METHODS FOR WT1 SPECIFIC
IMMUNOTHERAPY

Examiner : Ronald B. Schwadron
Art Unit : 1644
Docket No. : 210121.465C2
Date : July 25, 2002

Commissioner for Patents
Washington, DC 20231

RESPONSE TO RESTRICTION REQUIREMENT AND PRELIMINARY AMENDMENT

Commissioner for Patents:

In response to the Restriction Requirement dated March 26, 2002, please extend the period of time for response three (3) months, to expire on July 26, 2002. Enclosed are a Petition for an Extension of Time and the requisite fee.

In response to the Restriction Requirement dated March 26, 2002, applicants hereby elect Group I, claims 1-9, drawn to peptides and compositions and vaccines containing said peptide, and species SEQ ID NO:144, for examination at this time.

Please amend the above identified application as follows:

In the Claims:

Please cancel non-elected claims 2 and 10-45.

Please cancel claims 3-5 and 8-9.

Please amend claims 1, 6, and 7 to read as follows:

1. (Amended) A polypeptide comprising an immunogenic portion of a native WT1, or a variant thereof that differs in one or more substitutions, deletions, additions and/or insertions such that the ability of the variant to react with WT1-specific antisera and/or T-cell

B1